C ystic fibrosis (CF) is the most common life-threatening recessive genetic disease in the Caucasian population (1) . Due to mutations in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR), the expression of the CFTR protein in epithelial cells is disturbed. This results in dysfunctional anion transport [primarily chloride (2) and bicarbonate (3) anions] across the plasma membrane. The lack of a proper anion flow in epithelial cells causes complications in a variety of organs in the human body, including chronic airway infection and obstruction, pancreatic insufficiency, and intestinal obstruction (4) . Although advances in diagnosis and therapies have significantly improved the life quality and life expectancy of CF patients, the median life expectancy in the United States is still below 40 y (38.7 for males and 36.0 for females) (5) .
More than 1,900 different CFTR mutations have been identified to cause CF (6) . These mutations can be divided into different classes according to the mechanism by which they disrupt CFTR expression (7) . Most patients suffer from a class II mutation, including the deletion of a phenylalanine residue at position 508, F508del, which is present in ∼70% of the CF alleles in patients in Europe, North America, and Australia (8) . In cells containing class II mutations, transcription and translation of the CFTR protein is successful, but the protein is only partly glycosylated, misfolded, and retained in the endoplasmic reticulum (ER) (9) . The immature protein is recognized by CHIP/Hsc70 cochaperones, which results in the retrotranslocation of CFTR from the ER and its subsequent degradation by the ubiquitinproteasomal pathway (10) . Nevertheless, when the mutated CFTR is stimulated to be transported to the plasma membrane, for example by reducing the temperature of the cell, its chloride secretion is often still partially functional (11) .
Earlier research has shown that 14-3-3 proteins play an important role in the biogenesis of the CFTR protein (12, 13 ). 14-3-3 is a eukaryotic adaptor protein family that consists of seven isoforms (β, γ, e, ζ, η, σ, and τ) (14) . Isoforms β, γ, and e have been shown to be present in human bronchial epithelial cells, whereas other isoforms have been shown to be weak or absent. Additionally, phosphorylation-dependent binding of 14-3-3β and 14-3-3e to the regulatory (R) domain of CFTR has been shown to significantly increase the CFTR level in the plasma membrane (13) . As an explanation, 14-3-3 is considered to reduce retrieval of the CFTR protein to the ER by masking the ER retention signal and assisting folding and maturation of the protein Significance It has been shown that 14-3-3 proteins increase trafficking of cystic fibrosis transmembrane conductance regulator (CFTR) to the plasma membrane by binding to its regulatory (R) domain. This paper contains a detailed characterization of the 14-3-3/CFTR interaction, showing that multiple phosphorylated binding sites in the CFTR R-domain are necessary for significant binding with 14-3-3. We find that one of these binding sites serves as an anchor, while surrounding weaker sites enhance the interaction. Furthermore, we show the druggability of this interaction using natural-product fusicoccin-A, which stabilizes the 14-3-3/CFTR interaction by selectively modifying a weaker binding site. This mechanism of action can serve as a model for the development of new trafficking corrector molecules to treat cystic fibrosis. (15, 16) . This makes the binding between CFTR and 14-3-3 a highly interesting protein-protein interaction (PPI).
The intrinsically disordered R domain of the CFTR protein bears nine different motifs that could, upon phosphorylation, bind to 14-3-3 ( Fig. 1 A and B) (13, 17) . Additionally, 14-3-3 proteins naturally form dimers, which contain two adjacent amphipathic binding grooves capable of simultaneously binding one or more protein partners (18, 19) . The numerous binding possibilities hereby arising make the interaction between 14-3-3 and CFTR an exceptionally complex 14-3-3 PPI. To investigate how this interaction actually occurs, Liang et al. (13) estimated the occupancy of the bound state of these different binding motifs to 14-3-3β. Furthermore, Bozoky et al. (20) constructed several models for this interaction based on the chemical shift of the R domain upon binding to 14-3-3. However, only minimal quantitative data on the binding interaction of these nine different motifs have yet been published, and the role of the multivalency of the interaction remains unclear.
The increased trafficking to the plasma membrane of CFTR by binding to 14-3-3 might offer a therapeutic approach for the treatment of CF. Stabilization of the interaction between 14-3-3 and the mutated CFTR, for example through binding of a small molecule, could improve the trafficking of CFTR to the cell surface and hence increase chloride transport over the plasma membrane. The design of such therapeutically useful stabilizing molecules could be facilitated by solving the complex structure of the 14-3-3-CFTR interaction. In this study, we disentangle this complex but important PPI on a chemical biology and structural biology basis. Here, we use the 14-3-3 tool compound fusicoccin-A (FC-A) to stabilize the 14-3-3-CFTR interaction as a basis for the design of novel therapeutics for CF.
Results
Binding Affinities of the Interaction Between CFTR R-Domain Peptides and 14-3-3β. The separate binding motifs in the R domain were investigated to resolve the binding mechanism between the intrinsically disordered CFTR R domain and the 14-3-3 protein. Peptides corresponding to the nine possible 14-3-3 binding motifs were synthesized (Fig. 1B) , with the phosphorylated serine in the center surrounded by six amino acids of the natural sequence on each side. After N-terminal labeling with fluorescein isothiocyanate (FITC), a fluorescence polarization (FP) assay was performed to measure the binding of these labeled peptides to 14-3-3β. Remarkably, none of the nine peptides of 14-3-3 had sufficient affinity to allow determination of the association constants ( Fig. 2A) . However, the results from the assays showed the pS768 peptide to be the strongest binder.
Because a 14-3-3 dimer contains two binding grooves that are known to simultaneously bind two epitope sites on the same target protein partner, a series of diphosphorylated CFTR peptides were synthesized to study a potential dual-binding mechanism for CFTR. These peptides each consisted of two adjacent binding motifs, including the native interconnecting peptide sequences and an additional six amino acid residues at both the N and C termini (Fig. 1C) . The peptides were N-terminally labeled with FITC, and results from an FP assay showed that most of them bound to 14-3-3β with significantly stronger affinity than the singly phosphorylated peptides (Fig. 2B and Fig. S1A ), with K d values typically in the low micromolar range. The strongest binder in this assay was CFTR_R7, which features the pS768 and pS795 epitopes, followed by CFTR_R6, featuring pS753 and pS768. Interestingly, both of these peptides contain the pS768 binding motif, which by itself showed the strongest individual binding to 14-3-3β. However, peptides not containing the pS768 binding motif also showed a stronger affinity for 14-3-3β than the singly phosphorylated peptides, especially CFTR_R8, which features pS795 and pS813. During these experiments, one of the physically most relevant isoforms, 14-3-3β, was used. However, the other six isoforms were also tested to investigate the isoform dependence of the CFTR R-domain peptides. Hence, FP assays of peptides CFTR_R1-CFTR_R8 were performed on all seven isoforms. The results showed that in all cases 14-3-3γ binds the strongest, followed by η, β, ζ, e, τ, and σ, respectively (Fig. S1A) . The results from this experiment also showed that CFTR_R7 and CFTR_R6 exhibit the strongest binding to all seven 14-3-3 isoforms.
Data from isothermal titration calorimetry (ITC) measurements on the three strongest-binding peptides showed the same trend in binding to 14-3-3β as observed in the FP assay. The binding affinities of CFTR_R6, CFTR_R7, and CFTR_R8 for 14-3-3β were 75.8, 24.0, and 370 μM, respectively (Fig. 2 C-E and Fig. S2 A-C) . Additionally, the ITC measurements show in all cases the stoichiometry of the CFTR peptide versus the 14-3-3 protomer to be close to 0.5 (Fig. S2D ). This suggests that one peptide containing two phosphorylated binding motifs is binding to one 14-3-3 dimer.
The intrinsically disordered nature of the CFTR R domain could potentially also allow the R domain to bind with two nonadjacent binding motifs to one 14-3-3 dimer. Therefore, peptide probes featuring two nonadjacent binding motifs, the pS768 motif and a more distant motif, were synthesized. These two motifs were connected by a glycine linker to reduce the peptide length and overcome synthesis problems while mimicking the flexibility of the R domain (CFTR_R9 and CFTR_R10). ITC measurements of these two peptides showed binding to 14-3-3β comparable to CFTR_R6 and CFTR_R7 featuring adjacent binding motifs (Fig. S3 A-C and H) .
To confirm that these potential phosphorylated sites are relevant for 14-3-3 binding, the wild-type R domain and the R domain containing a S700A, S753A, or S768A mutation were coexpressed with PKA. These mutations were constructed to prevent phosphorylation of the mutation site to study the influence of each site on the binding of the CFTR R domain to 14-3-3β. Although the coexpression with PKA resulted in only a partially phosphorylated R domain (a variation of three to nine phosphoryl groups was attached to the R domain; Dataset S1, W-AA), eliminating the serine at position 768 shows a significant decrease in binding affinity to 14-3-3β (56.5-125.9 μM) whereas the other positions (700 and 753) resulted in a smaller decrease (59.9 and 92.6 μM, respectively) ( Fig. S3 D 
-H).
Crystal Structure of CFTR_R6 and CFTR_R7 with 14-3-3. The doubly phosphorylated peptide CFTR_R6 was cocrystallized with 14-3-3ζ, and the protein complex structure was solved to a resolution of 2.1 Å [Protein Data Bank (PDB) ID code 5D2D] (Fig. 3) . Interpretable density for 19 out of 28 amino acids of the CFTR_R6 peptide (R751-G758 and R764-T774) was found ( Fig. 3 A and B) . The protein structure shows that both phosphorylated binding motifs of the peptide are simultaneously bound to one 14-3-3 dimer. The pS768 site is located in the binding groove of 14-3-3 protomer A, and the pS753 site is located in 14-3-3 protomer B (Fig. 3 A and B) . The five residues of the flexible, connecting linker are not visible in the electron density. The phosphorylated serines are located in the basic pocket of 14-3-3, composed of Arg56 and Arg127, consistent with earlier published structures of cocrystallized phosphorylated peptides with 14-3-3 ( Fig. 3 C-E) (21-23). Fig. 3E shows more details of the interaction between protomer A and the pS768 binding site. The polar contacts are visualized by dashed lines and are more relevant for the binding of the N-terminal part of the peptide, whereas hydrophobic interactions, depicted as semitransparent spheres, are more relevant for accommodation of the C-terminal half of CFTR (pS768). The most prominent interaction is the basic pocket in 14-3-3 composed of Arg56 and Arg127 binding pS768, stabilized by polar contacts with Tyr128. Further on, polar contacts can be seen of Arg766 and Arg765 of CFTR_R6 with Glu180 and Glu131 of 14-3-3 (directly or via a water molecule). These interactions are generally responsible for the known mode I and mode II binding of 14-3-3. Additionally, Leu770 and Leu772 form important hydrophobic interactions with Val46 and Phe117 of 14-3-3. The distance between G758 and R764 (31.5 Å) is too large to be bridged by the five amino acids connecting these two amino acids. However, this can be explained by the packing of the CFTR_R6-14-3-3ζ crystal (Fig.  S4A) . The position of the symmetry elements shows tetramer formation of the 14-3-3 proteins. The distance between the C terminus of the pS753 binding site and the N terminus of the pS768 binding site is 15.3 Å, which is short enough to be bridged by five amino acids. However, this tetramer formation is most probably due to packing in the crystal lattice, because additional experiments (size-exclusion chromatography, cross-linking, dynamic light scattering, and small-angle X-ray scattering) did not produce evidence for the presence of 14-3-3 tetramers in solution.
The doubly phosphorylated peptide CFTR_R7 was cocrystallized with 14-3-3γ. This protein complex structure was solved to a resolution of 2.75 Å (PDB ID code 5D3E) (Fig. S5) . Here, interpretable density was found for 11 of the 40 amino acid residues present in the CFTR_R7 peptide (R766-L770 and K793-P798) (Fig. S5B) . The structure of 14-3-3γ-CFTR_R7 shows that, as for the CFTR_R6 structure, both phosphorylated binding motifs are simultaneously bound to the 14-3-3 dimer: pS768 is located in the binding groove of 14-3-3 protomer A, and pS795 is located in protomer B (Fig. S5A) .
Stabilization of the 14-3-3-CFTR Interactions with Fusicoccin-A. PPIs involving 14-3-3 proteins have been shown to be stabilized by small molecules (24) (25) (26) . To examine the principal possibility of stabilizing the 14-3-3-CFTR interaction, a number of these known 14-3-3 stabilizers were tested on this interaction. The presence of 100 μM FC-A (Fig. 4E ) in the FP assay stabilized the binding of CFTR_R6 to 14-3-3, increasing the apparent affinity by a factor of 4.0, from a K d of 15.9 μM to a K d of 3.98 μM (Fig. 4A and Fig. S1B ). ITC measurements confirmed this with an increased binding affinity of CFTR_R6 to 14-3-3 in the presence (Fig. 4 B and C) . In contrast, addition of FC-A did not result in a significant increase in the binding affinity of the 14-3-3-CFTR_R7 interaction (Fig. 4 A-C and Fig. S1B) .
To determine the structural basis for the observed stabilization of the 14-3-3-CFTR_R6 complex by FC-A, the compound was soaked into the crystals described above. The structure was solved to a resolution of 2.74 Å (PDB ID code 5D3F) (Fig. 4 D-G) . Interpretable density was found for 18 of the 28 amino acids present in the CFTR_R6 peptide (R750-L756 and K764-P774) (Fig. 4D) , with FC-A present in one binding groove of the 14-3-3 dimer (Fig. 4D) . The difference density map directly calculated after molecular replacement with only 14-3-3 and the CFTR_R6 peptide as search model, but excluding FC-A, showed unambiguous, unbiased density for FC-A (Fig. S4B ) in 14-3-3 protomer B containing the pS753 binding motif but not in 14-3-3 protomer A containing the pS768 binding motif. Compared with the structure of the binary complex, the pS753 peptide motif adapts its conformation slightly to enable the FC-A molecule to bind between the 14-3-3 protein and the CFTR peptide (Figs. 3D and 4F). Although there are some polar contacts between FC-A and 14-3-3 residues (Asn42, Lys122, and Asp215), no polar contacts are observed between FC-A in the pS753 binding motif of CFTR_R6. In essence, 14-3-3 and the peptide jointly form a hydrophobic pocket that accommodates the mostly hydrophobic FC-A molecule (Fig. 4G ). FP assays of CFTR_R6 with both physiologically relevant 14-3-3 isoforms β and e, and 14-3-3ζ (which is used in the crystal-soaking experiment), show that FC-A increases the binding affinity of CFTR_R6 for all three 14-3-3 isoforms (Fig. S1B) .
The CF mutation database (www.genet.sickkids.on.ca/Home.html) contains mutations that lead to CF and could influence the binding of the CFTR R domain to 14-3-3. Examples are S753R, V754M, and R766M. To test the influence of these mutations on the binding to 14-3-3, peptides similar to CFTR_R6 (pS753-pS768) were synthesized that contain these mutations. After N-terminal labeling with FITC, their affinity for 14-3-3β was tested with an FP assay (Fig. S3I) showing that these three peptides all bind less strongly to 14-3-3β than the CFTR_R6 wild-type peptide, further hinting at the relevance of the 14-3-3-CFTR interaction for CF.
Influence of FC-A on the Trafficking of F508del-CFTR. To examine the effects of FC-A on the trafficking of F508del-CFTR in the cell, baby hamster kidney (BHK) cells expressing 3HA-tagged F508del-CFTR were treated for 24 h with different concentrations of FC-A. After fixation of the cells, the combination of mouse monoclonal anti-HA antibody and anti-mouse IgG conjugated with FITC was used to detect F508del-CFTR that had trafficked to the plasma membrane, as described before by Carlile et al. (27) . Increased fluorescence was detected with increasing concentrations of FC-A, up to 54% of a positive control, VX-809 [a known F508del-CFTR corrector (28) ], at 100 μM (Fig. 5A) .
Discussion
In recent years, the amount of research done on 14-3-3 proteins has increased significantly. Each year, new protein binding partners for 14-3-3 are found and, with them, the number of diseases and possible therapeutic approaches related to 14-3-3 increases (29) . This brings forward a strong need to understand the different binding mechanisms of this regulatory hub protein. Although a great number of 14-3-3 interactions have been thoroughly quantified, analyzed, and structurally elucidated (22, 23, (30) (31) (32) , the interaction between CFTR and 14-3-3 remains poorly understood. The binding of the intrinsically disordered CFTR R domain to 14-3-3, relying on multiple-phosphorylated 14-3-3 binding motifs, employs a unique binding mechanism. There are several 14-3-3 PPIs known where proteins with multiple-phosphorylated serines Table S1 for data collection and refinement details.
and threonines interact with 14-3-3, for example LRRK2, p53, and BAD (30, (33) (34) (35) (36) . However, the CFTR R-domain interaction with 14-3-3 is exceptional for the large number of interaction sites (nine). Apart from increasing our understanding of the interactions and specificity of 14-3-3 proteins, we have shown that stabilization of this interaction might present a mechanism for tackling the trafficking defect of the F508del-CFTR mutant protein.
FP binding assays of the nine singly phosphorylated CFTR peptides with 14-3-3β show that their binding to 14-3-3 is weak (≥high micromolar range) (Fig. 2A) . These individual affinities are too low to explain the biological function of 14-3-3 in CFTR expression as described in a publication of Liang et al. (13) , and are significantly lower than the affinity of the whole phosphorylated R domain to 14-3-3 published by Bozoky et al. (K d based on Trp fluorescence measurements: 5.4 ± 1.0 μM) (20) . The affinities of the doubly phosphorylated CFTR peptides to 14-3-3 are significantly stronger (low-middle micromolar range) (Fig.  2B ) and comparable to those of earlier published 14-3-3 interaction partners (18) as well as the full-length R domain (20) . Therefore, the 14-3-3 dimer most probably binds simultaneously to two monophosphoepitope sites on the same CFTR R domain. Bozoky et al. reported a variety of different binding modes in their NMR-based model for CFTR R-domain binding to 14-3-3 (20) . Our structures of CFTR_R6 and CFTR_R7 with 14-3-3 clearly demonstrate that the phosphorylated binding sites do bind in the amphipathic binding grooves of 14-3-3, although the connecting linker in-between is not visible in the electron density and therefore shows no evidence for a functional interaction with 14-3-3 ( Fig. 3 and Fig. S5) .
In binding assays, 14-3-3β was used because this isoform is physically relevant in CFTR expression (13) . However, for practical reasons, 14-3-3ζ and 14-3-3γ have been used in crystallography experiments. Although these isoforms are physiologically less relevant, the binding grooves of 14-3-3 are highly conserved among the different isoforms (37) , and should therefore provide a reliable impression of the binding between the R domain and 14-3-3. Additionally, the FP assay of all eight doubly phosphorylated peptides with the seven different isoforms showed that there are no specific preferences for the different binding sites within the isoforms (Fig. S1) . Although the different isoforms show different total binding affinities, they display the same trend in binding to the different peptides.
The nine 14-3-3 binding sites in the R domain are all related to the mode I (RSXpSXP) and/or mode II (RX[Y/F]XpSXP) 14-3-3 binding motifs (32) , but none of the motif sequences present in CFTR conform exactly to either of these two modes. The R-domain binding site corresponding best to these published consensus binding sites is pS768 (QARRRQpSVLNLMT) (Fig. 1B) . Accordingly, pS768 scored the maximum value in the overview of the estimated relative occupancy of the bound state of the nine different 14-3-3 binding sites in the CFTR R domain (13) . These observations are coherent with our experimental findings that indeed pS768 is the strongest individual binding site of the CFTR R domain to 14-3-3. Furthermore, we expected, based on the amino acid sequence and the estimated relative occupancy of the bound state of Liang et al. (13) , that pS795 would bind more strongly to 14-3-3 than pS753. Our quantification of the binding of CFTR_R6 (pS753-pS768) and CFTR_R7 (pS768-pS795) to 14-3-3 in both the ITC and FP assays confirms this prediction (Fig. 2) . However, there are further alternative bivalent modes of CFTR binding to 14-3-3 imaginable. To test some of the possible combinations of two CFTR phosphosites binding to 14-3-3, we synthesized CFTR_R9 (pS712-G 5 -pS768) and CFTR_R10 (pS768-G 5 -pS813), which showed a comparable binding affinity for 14-3-3 as CFTR_R7 (Fig. S3) . Although these peptides are not exactly similar to the natural sequence, because both the sequence and length of the glycine linker in the peptide are different from the natural sequence, these results provide valuable insight into the possibility that nonadjacent binding motifs can bind simultaneously to 14-3-3. Additionally, ITC experiments performed on the full R domain showed that phosphorylation of S768 is more important for the binding to 14-3-3 than, for example, phosphorylation of S700 and S753 (Fig. S3 D-H) .
What is the role for the multiple-phosphorylated 14-3-3 binding sites in the CFTR R domain? One explanation could be that pS768 acts as a main anchor point for the binding between CFTR and 14-3-3. After the binding of one 14-3-3 protomer to this anchor point, the local concentration of weaker binding sites surrounding the other protomer increases significantly, making the binding of a second protomer more likely to happen (Fig. 6 ). This mechanism is described by Yaffe as the "gatekeeper" model: One dominant site functions as an initiator that must be present and phosphorylated to promote a 14-3-3 interaction, which is then stabilized by a second interaction (38) . However, the case of CFTR is exceptional for the large number of binding sites, of which at least two must be phosphorylated and one has to be pS768. In this way, a mutation to one of the eight weaker binding sites will not significantly affect the functionality of CFTR, whereas having one single anchor point minimizes the chance of multiple 14-3-3 proteins binding to one R domain. Another explanation is more biological. 14-3-3 proteins are expected to increase CFTR function in three different ways: (i) supporting the folding of CFTR, (ii) masking the degradation recognition site, and (iii) assisting the trafficking to the plasma membrane (13, 39) . Binding of certain sites of the R domain to 14-3-3 could support the folding of the protein, whereas binding of other sites could, for example, mask or present the COPI recognition sites. These sites are located in the CFTR R domain at positions 683 (KKQS) and 696 (KRKNS) (40, 41) .
Phosphorylation of the CFTR R domain significantly increases its binding to 14-3-3 (K d based on Trp fluorescence measurements shifts from 34.3 ± 7.4 μM to 5.4 ± 1.0 μM) (20) . Therefore, we should keep in mind that the phosphorylation positions of the R domain and the presence of certain kinases exert an important influence on the binding of 14-3-3 to CFTR. A prediction of phosphorylation sites shows that different kinases are capable of phosphorylating different 14-3-3 binding sites. For example, PKA is able to phosphorylate all nine sites, PKC is predicted to phosphorylate only eight (all but Ser753), and AMPK is able to phosphorylate only five sites (Ser700, Ser737, Ser768, Ser795, and Ser813) (42) . This can cause different levels of phosphorylation at different sites, varying over time, location, and cell fate. In this sense, the multiphosphorylatable R domain could work as an integrator of different signal-transduction pathways, with 14-3-3 acting as a "reader" element of the different phosphorylation patterns. Johnson et al. characterize this as an "AND" gate, where two phosphorylated sites must be engaged before the 14-3-3 dimer can bind, so two inputs (phosphorylation of the R domain by two different kinases) can lead to one output (binding of 14-3-3 to the CFTR R domain) (43) . Furthermore, multiphosphorylation of the R domain could lead to an ultrasensitive response of binding to the 14-3-3 protein. We discovered with this study that at least two phosphorylated binding sites in the R domain, of which one should be pS768, are needed for the interaction with 14-3-3. The "extra" phosphorylation sites are perhaps not per se essential for binding to 14-3-3 but can increase the sensitivity of the system, resulting in a switch-like mechanism. Ferrell and Ha describe this phenomenon in an excellent review (44) where the Fus3-Ste5 interaction is used as an example. This interaction is important in yeast mating, where an ultrasensitive response is generated by multisite phosphorylation, two-stage binding with one docking site, and steric hindrance (45) . The results reported here provide the first indications, to our knowledge, toward a potential similar ultrasensitive mechanism for regulation of the 14-3-3-CFTR interaction. Interestingly, the Table S1 for data collection and refinement details.
CF mutation database contains CF mutations that are present in the 14-3-3 binding sites of the CFTR R domain. We show with an FP assay of the CFTR_R6 peptide containing a selection of these mutations (S753R, V754M, and R766M) that they can decrease the binding affinity of the CFTR R domain to 14-3-3 (Fig. S3I) . This indicates that interruption of this PPI could be the underlying mechanism in a certain mutation class of the disease.
To analyze the possibility of stabilizing the 14-3-3-CFTR interaction, known stabilizers for 14-3-3 PPIs were tested in binding assays between 14-3-3 and the different doubly phosphorylated CFTR peptides. Addition of 200 μM FC-A resulted in a ninefold increase of affinity between 14-3-3β and CFTR_R6. Interestingly, until now, FC-A was reported to only stabilize mode III binding motifs ([pS/pT]X-COOH, where X is not Pro) (22) , and yet the R domain does not contain any mode III binding sites. The structure of 14-3-3-CFTR_R6 crystals soaked with FC-A shows that FC-A is only present in the binding groove containing the pS753 binding site (Fig. 4D) . This is possibly the reason why the FP assays and ITC measurements showed that FC-A is able to stabilize the 14-3-3-CFTR_R6 (pS753-pS768) interaction but not the 14-3-3-CFTR_R7 (pS768-pS795) interaction (Figs. 4 A-C and 5) . The most important interactions between FC-A and CFTR_R6 are the hydrophobic contacts with Val754 and Ile755, which form a hydrophobic pocket together with 14-3-3 residues Leu218, Ile219, Ile168, and Val64 (Fig. 4G) . However, the pS768 and pS795 binding motifs also display hydrophobic residues at the +1 and +2 positions of the phosphorylated serine but are not stabilized by FC-A. A possible explanation why the pS768 motif is not stabilized by FC-A is that Leu772 contains hydrophobic contacts with both the Phe117 of 14-3-3 and Leu770 of the peptide itself (Fig. 4E) , which would be broken by addition of FC-A in this pocket, leading to a decreased binding affinity.
Furthermore, a possibility is that leucine and alanine of the pS795 binding site, and valine and leucine of pS768, do not form the right surface topography to present to FC-A. Another explanation could be that the short linker between pS753 and pS768 (14 amino acids) is "guided" toward the direction of the second binding groove by FC-A, which is not essential for the longer linker between pS768 and pS795 (26 amino acid residues). This would explain why the other doubly phosphorylated, but weaker-binding, peptides containing short linker lengths, CFTR_R1 (pS660-pS670) and CFTR_R3 (pS700-pS712), show stabilization upon addition of FC-A as well (Fig. S6B ), whereas peptides with longer linker lengths and the singly phosphorylated peptides do not show a significant increase of affinity through addition of FC-A (Figs. S6 and S7 ). FP assays of CFTR_R6 with both physiologically relevant 14-3-3 isoforms β and e, and ζ, showed that there is no isoform specificity in stabilization of the 14-3-3-CFTR interaction (Fig. S1B) . In this manner, tool compound FC-A shows the "ligandability" of the 14-3-3-CFTR interaction in an intermolecular specific manner. The difference between the mode I/II binding of pS753 to 14-3-3 and the mode III binding of other known 14-3-3 PPIs that can be stabilized with FC-A could provide the stabilization specificity needed for further drug discovery.
Carlile et al. developed a sensitive F508del-CFTR cell-based assay to detect correctors of trafficking (27) . This assay showed that FC-A increases F508del-CFTR trafficking to the plasma membrane, up to 54% of the positive control VX-809 (at a concentration of 100 μM; Fig. 6A ), thus confirming the biological relevance of the 14-3-3-CFTR PPI and its small-molecule stabilization. This makes FC-A an F508del-CFTR trafficking corrector with a structurally known mechanism of action, which is rare in the field. In conclusion, we have presented a thorough and quantitative biophysical and structural characterization of the interaction between 14-3-3 and CFTR, and provided clear evidence for a tandem mode-of-action binding event. One anchor binding motif of CFTR (pS768) occupies one binding groove of the 14-3-3 dimer, and a weaker, secondary binding motif (e.g., pS712, pS753, pS795, or pS813) occupies the other binding groove. Additionally, we show that the 14-3-3-CFTR interaction can be specifically stabilized by targeting the secondary binding-motif interaction with 14-3-3 with the small-molecule stabilizer FC-A, which thus might display a possible corrector activity in the trafficking of F508del-CFTR. The characterization of the 14-3-3-CFTR interaction presented in this paper is an important step in understanding the purpose of multisite phosphorylation in disordered domains to initiate 14-3-3 PPIs. Furthermore, it provides a promising approach for CF drug discovery.
Materials and Methods
Reagents. Fusicoccin-A was obtained from Enzo Life Sciences.
Peptide Synthesis. All peptides were synthesized via Fmoc solid-phase peptide synthesis (SPPS), either manually or using an automated Intavis MultiPep RSi peptide synthesizer. Rink amide AM resin (Novabiochem; 0.59 mmol/g loading) was used to synthesize the singly phosphorylated peptides, and TentaGel R RAM resin (Rapp Polymere; 0.18 mmol/g loading) was used for the synthesis of the diphosphorylated peptides. Pseudoproline dipeptides (respectively QS and AS; Novabiochem) were used for the synthesis of CFTR_R2 and CFTR_R7. The peptides used for ITC measurements and for crystallization studies were acetylated at the N terminus (1:1:3 Ac 2 O/pyridine/ NMP) before resin cleavage. The peptides used for FP assays were labeled with FITC (Sigma-Aldrich) attached to a short polyethylene glycol-based linker introduced via Fmoc-O1pen-OH (Iris Biotech) under the standard SPPS conditions. All peptides were purified by preparative reversed-phase HPLC with MS detection (Dataset S1).
14-3-3 Expression. His 6 -tagged 14-3-3 isoforms (full-length and ΔC) were expressed in NiCo21(DE3) competent cells with a pPROEX HTb plasmid and purified with a nickel column. The His 6 tag was cleaved off using TEV protease, and a second purification was performed by size-exclusion chromatography. The proteins were dialyzed against FP, ITC, or crystallization buffers before use (procedures are described below).
Fluorescence Polarization Assay. The FITC-labeled peptides were dissolved in FP buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 0.1% Tween 20, 1 mg/mL BSA) to a final concentration of 100 nM. Dilution series of 14-3-3β were made on Corning black round-bottom 384-well plates, and their polarization was measured on a Tecan Infinite F500 plate reader (excitation 485 nm, emission 535 nm). During the PPI stabilization experiments, FC-A was dissolved in DMSO (10 mM) before addition to the peptide solution to a final concentration of 100 μM [final DMSO concentration 1% (vol/vol)].
Isothermal Titration Calorimetry. The ITC measurements were performed on a Malvern MicroCal iTC200. The cell contained 0.2 mM 14-3-3β and the syringe contained 1.0 mM peptide, both in ITC buffer [25 mM Hepes, pH 7.4, 100 mM NaCl, 10 mM MgCl 2 , 0.5 mM Tris-(2-carboxyethyl)-phosphin]. Two repetitions of a series of 18 2-μL titrations were performed at 37°C (reference power, 5 μCal/s; initial delay, 60 s; stirring speed, 750 rpm; spacing, 180 s), and the data were merged with ConCat32 software (MicroCal). For the PPI stabilization experiments, FC-A was dissolved in ethanol, which was evaporated before addition of Fig. 6 . Overview of the interaction between the intrinsically disordered CFTR R domain (blue) and the 14-3-3 dimer (gray) with two amphipathic binding grooves. Binding of the strongest binding site (pS768; red sphere) increases the local concentration of the weaker binding sites of the R domain (orange spheres), followed by a second binding event (e.g., pS712, pS753, pS795, or pS813). All interactions are individually weak. However, the combination of the two binding sites creates a stronger interaction. FC-A has been shown to stabilize specifically at the pS753 binding epitope. the protein. The final concentrations in these experiments were 0.1 mM 14-3-3β with 0.2 mM FC-A in the cell and 0.5 mM peptide in the syringe.
Crystallography. See SI Materials and Methods and Table S1 for details.
Cell Experiments. This experiment was performed as previously described by Carlile et al. (27) . In brief, 3HA-tagged F508del-CFTR-expressing baby hamster kidney cells were seeded in 96-well plates (Corning; half-area, black-sided, clearbottom) at 15,000 cells per well. After a 24-h incubation at 37°C, the cells were treated with different concentrations of FC-A or VX-809 for 24 h [final DMSO concentration 1% (vol/vol)]. The cells were fixed with 4% (vol/vol) paraformaldehyde, washed with PBS, and then blocked with FBS [5% (vol/vol) in PBS]. Mouse monoclonal anti-HA antibody (Sigma; 1:150 dilution in PBS) was incubated overnight, and after three washes with PBS the background fluorescence was measured on a plate reader (excitation 488 nm, emission 510 nm). The secondary antibody anti-mouse IgG conjugated with FITC (Sigma; 1:100 dilution in PBS) was incubated for 1 h, and the cells were washed three times with PBS and analyzed on the plate reader again. Background fluorescence was subtracted from the signal, after which the signal was normalized to the DMSO control.
